Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up.
Mazariegos
G V
GV
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
Reyes
J
J
Marino
I
I
Flynn
B
B
Fung
J J
JJ
Starzl
T E
TE
D002648:Child; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D011183:Postoperative Complications / Q000453:epidemiology*; D013997:Time Factors
D007166:Immunosuppressive Agents